# Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

> **NCT01362608** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 136 (actual)

## Conditions studied

- Gouty Arthritis

## Interventions

- **DRUG:** Canakinumab, ACZ885
- **DRUG:** Triamcinolone acetonide

## Key facts

- **NCT ID:** NCT01362608
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-20
- **Primary completion:** 2015-05-19
- **Final completion:** 2015-05-19
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362608, "Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01362608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*